Research Mentor Name

Dragana Komnenov

Research Mentor Email Address

Institution / Department

Wayne State School of Medicine / Internal Medicine, Nephrology

Document Type

Research Abstract

Research Type


Level of Research



Initial studies during the COVID-19 pandemic reported angiotensin converting enzyme 2 inhibitors (ACE2i) could be associated with worse disease course due to potential increase in ACE2 receptors which SARS-CoV2 virus uses for cellular entry. Subsequent studies refuted such concerns, reporting that continued use of ACEis and angiotensin receptor blockers (ARBs) in hypertensive individuals is protective. However, there remains a paucity of data evaluating effects of various antihypertensive medications, steroids, and beta blockers in chronic kidney disease (CKD) populations and in individuals with normal kidney function. This study was designed to evaluate the potential risks associated with antihypertensive medications and COVID-19 outcomes in a cohort of mostly Black and Caucasian patients admitted to the Detroit Medical Center for COVID-19. We collected data from 330 patients using inclusion criteria of age > 18 years and a positive SARS-CoV2 PCR test. We used the mean, standard deviation/standard error of mean, and percentages when appropriate for the description of patient characteristics. Group differences (CKD vs. non-CKD) were compared using the Pearson χ2 test. P-values of <0.05 were regarded as significant. On regression analyses, the odds of death during hospitalization for COVID-19 infection was not significantly associated with either biological sex, race, or CKD status in our sample population. The odds of dying in the hospital were higher in patients who were on calcium channel blockers (OR 2.99, 95% CI 1.29-6.93) and steroids (OR 4.23, 95% CI 1.17-15.31). The only significance for ICU admission was obtained for steroid use (OR 1.872, 95% CI 1.059-3.311).


Infectious Disease | Internal Medicine | Nephrology